Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
Commentary|Articles|July 15, 2026
Kerry Rogers, MD, Talks BTK Inhibitor Sequencing, Cost, Access in CLL
Author(s)Maggie L. Shaw, Kerry Rogers, MD
Fact checked by: Laura Joszt, MA
Kerry Rogers, MD, at The James, unpacks what these questions mean for patient counseling and clinical trial equity in chronic lymphocytic leukemia (CLL).
Advertisement
Advertisement
The evolving Bruton tyrosine kinase (BTK) inhibitor landscape for
Related to this article
Experts explain why access to specialty cancer care, open dialogue, and patient education are essential to building trust and making informed treatment decisions.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
New non-CF bronchiectasis in Medicare is tied to high health care use and $8998 PPPM FFS spending; prevalence is highest in older women.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Postpartum navigation missed its primary goal but raised postpartum visits and primary care use among Medicaid-insured patients.
CMS' rule ending Medicaid and CHIP funding for pediatric sex-rejecting procedures is now in effect.
This analysis in RR MCL shows CAR T-cell therapy (brexucabtagene) yields higher complete responses vs bispecific antibodies; durability remains unclear.
Advertisement
Advertisement